Adenosine A2A Antagonists in Parkinsons Disease: Whats Next
Current Neurology and Neuroscience Reports, 06/08/2012
Hickey P et al. – The safety and efficacy of this class of compounds continues to be defined and future studies should focus on non–motor symptoms, dyskinesias, and neuroprotection.



